Akero Therapeutics posts Q2 2025 results update

Akero Therapeutics, Inc. filed a current report disclosing that it has announced its financial results for the quarter ended June 30, 2025.

Accepted by SEC EDGAR 08/08/2025 - 07:37 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Akero Therapeutics, Inc. filed a current report disclosing that it has announced its financial results for the quarter ended June 30, 2025. The company released these quarterly results through a press release dated August 8, 2025, which is included as Exhibit 99.1. This press release is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other SEC filings unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Akero Therapeutics (AKRO) report in this 8-K filing?

Akero Therapeutics reported that it announced its financial results for the quarter ended June 30, 2025, and furnished a related press release as Exhibit 99.1.

Which period do the latest Akero Therapeutics (AKRO) results cover?

The announced financial results cover the quarter ended June 30, 2025.

How is Akero Therapeutics providing its Q2 2025 financial results?

The company is providing its quarterly financial results through a press release dated August 8, 2025, furnished as Exhibit 99.1 to the report.

Are the Akero Therapeutics Q2 2025 results considered filed with the SEC?

No. The information in the report and in Exhibit 99.1 is furnished, not filed, and therefore is not subject to Section 18 liability and is not incorporated into other filings unless specifically referenced.

Who signed the Akero Therapeutics 8-K for the June 30, 2025 quarter?

The report was signed on behalf of Akero Therapeutics, Inc. by Andrew Cheng, M.D., Ph.D., its President and Chief Executive Officer.

What exhibits are included with this Akero Therapeutics (AKRO) 8-K?

The report includes Exhibit 99.1, the press release announcing the quarterly results, and Exhibit 104, the cover page interactive data file.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001744659 0001744659 2025-08-08 2025-08-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2025

Akero Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38944		81-5266573
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

601 Gateway Boulevard, Suite 350 South San Francisco, CA		94080
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (650) 487-6488

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		AKRO		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 8, 2025, Akero Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Akero Therapeutics, Inc. on August 8, 2025, furnished herewith.
104		Cover Page Interactive Data File

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 8, 2025				AKERO THERAPEUTICS, INC.
				By:		/s/ Andrew Cheng
				Name:		Andrew Cheng, M.D., Ph.D.
				Title:		President and Chief Executive Officer